MedPath

Packed Red Blood Cell Transfusion During Cardiac Arrest

Phase 1
Recruiting
Conditions
Cardiac Arrest
Interventions
Other: Saline
Drug: Packed Red Blood Cells (1 unit)
Drug: Packed Red Blood Cells (2 units)
Registration Number
NCT06462027
Lead Sponsor
NYU Langone Health
Brief Summary

The purpose of this pilot interventional study is to collect preliminary data on administering packed red blood cell (PRBC) during cardiac arrest (CA). The primary objective is to assess the feasibility of PRBC transfusion during cardiac CA to help optimize the methods required to augment cerebral and other vital organ oxygen delivery during cardiopulmonary resuscitation (CPR). The secondary objectives are to assess the effect of PRBC transfusion during prolonged cardiac arrests on cerebral oxygenation, end tidal carbon dioxide (ETCO2), return of spontaneous circulation (ROSC), survival to discharge, biomarkers of neural injury and inflammation, and neurological outcomes at hospital discharge, 30 days post-CA, and 90 days post-CA.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Adult patients, age ≥18 and <85 years
  • Experience prolonged, non-trauma-related in-hospital cardiac arrest, defined by cessation of heartbeat and respiration requiring CPR for at least 10 minutes
Exclusion Criteria
  • Age <18 years old
  • Age > 85 years old
  • Patients with DNR/DNI orders (Do Not Resuscitate/Do Not Intubate)
  • Patients admitted to the hospital with a cardiac arrest arising from trauma
  • Patients who achieve return of spontaneous circulation within 10 minutes of CPR
  • Inability to start study product administration within 20 minutes of cardiac arrest onset
  • Prisoners
  • Women who are known to be pregnant
  • Patients with a history of RBC antibodies or positive antibody screen prior to enrollment in the study, unless previously cross-matched units are available for transfusion.
  • Patients with ultrasound evidence of right ventricular dilatation at time of CA
  • Patients with known prior objection to receipt of blood products.
  • Patients for whom administration of additional fluid volume is contraindicated (as determined by physician responsible for care)
  • Physician objection based on concern that intervention would interfere with patient care plan

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Saline solutionSalineTreatment of 500 mL of normal saline.
Packed Red Blood Cells (1 unit)Packed Red Blood Cells (1 unit)500 mL of packed red blood cells
Packed Red Blood Cells (2 units)Packed Red Blood Cells (2 units)1000 mL of packed red blood cells
Primary Outcome Measures
NameTimeMethod
Time (in mins) to administration of Packed Red Blood Cells (PRBC)During Cardiopulmonary Resuscitation (CPR) (up to 20 minutes)
Change in frequency of right ventricular (RV) dilatationBaseline, up to 20 minutes post administration of PRBC
Proportion of patients with unfavorable neurological outcomesUp to 30 days post-Cardiac Arrest (CA)

The Cerebral Performance Category (CPC) score is a five-point scale used to assess neurological outcome after cardiac arrest and other events. Scores range from 1 to 5, a score of 1 or 2 is considered a favorable outcome, and scores of 3, 4, or 5 are considered an unfavorable outcome (severe neurological disability, persistent vegetative state or death).

Frequency of antibody-mediated transfusion reactions6-72 hours after Return of Spontaneous Circulation (ROSC)

Outcome measure will be evaluated for the occurrence of intravascular and extravascular hemolytic reactions by measuring fibrinogen, D-dimer, platelet count, peripheral blood smear, and serum haptoglobin.

Frequency of non-immune reactions6-72 hours after ROSC

Non-immune reactions include Transfusion Associated Circulatory Overload (TACO) and Transfusion-Related Acute Lung Injury (TRALI) as determined by the Data Safety Monitoring Committee (DSMC).

All-cause mortalityUp to 30 days after the last day of study participation

Mortality due to all causes

Secondary Outcome Measures
NameTimeMethod
Relative change in peak rSO22 minutes prior to administration, 5 minutes post administration of PRBC
Relative change in mean rSO22 minutes prior to administration, 5 minutes post administration of PRBC
Rate of survival90 days post-CA
Relative change in peak end tidal carbon dioxide (ETCO2)2 minutes prior to administration, 5 minutes post administration of PRBC
CPC score90 days post-CA

The Cerebral Performance Category (CPC) score is a five-point scale used to assess neurological outcome after cardiac arrest and other events. Scores range from 1 to 5, a score of 1 or 2 is considered a favorable outcome, and scores of 3, 4, or 5 are considered an unfavorable outcome (severe neurological disability, persistent vegetative state or death).

Absolute change in peak regional oxygen saturation (rSO2)2 minutes prior to administration, 5 minutes post administration of PRBC
Absolute change in mean rSO22 minutes prior to administration, 5 minutes post administration of PRBC
Relative change in mean ETCO22 minutes prior to administration, 5 minutes post administration of PRBC
Proportion of patients with release of pro-inflammatory cytokines6-72 hours after ROSC
Proportion of patients with release markers of brain injury6-72 hours after ROSC
Rate of ROSCDuring CPR (up to 20 minutes)

Trial Locations

Locations (1)

NYU Langone Health

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath